期刊文献+

糖尿病下肢血管病变与血浆内脏脂肪素的关系 被引量:3

A relationship between lower limb vascular disease and plasma visfatin in patients with T2DM
原文传递
导出
摘要 目的研究2型糖尿病(T2DM)患者不同程度的下肢血管病变与血浆内脏脂肪素的关系。方法选择泰安地区的T2DM患者112例,根据临床症状和下肢动脉彩色多普勒超声情况,分为单纯T2DM组42例,糖尿病合并轻度下肢动脉硬化(T2DM-MLAD)组38例和糖尿病合并重度下肢动脉硬化(T2DM-SLAD)组32例,另选取正常对照(NC)组40名。测定内脏脂肪素和其他相关临床指标,进行数据统计。结果 NC组与单纯T2DM组相比内脏脂肪素无统计学差异[分别(46.79±7.67)和(50.86±11.65)ng/ml,P>0.05],T2DM-MLAD组和T2DM-SLAD组内脏脂肪素[分别(58.75±13.52)和(67.21±16.6)ng/ml]均明显高于NC组和单纯T2DM组(P<0.01),T2DM-SLAD组又明显高于T2DM-MLAD组(P<0.01)。Pearson相关分析表明,内脏脂肪素与WHR、FIns、HOMA-IR、下肢血管内膜中层厚度(IMT)、HbA_1c呈正相关。踝肱指数(ABI)随糖尿病下肢动脉病变的出现与加重而逐渐降低。结论内脏脂肪素与T2DM患者下肢血管病变程度明显相关,是下肢动脉硬化的危险因素。 Objective To study the relationship of the lowerlimb vascular disease with plasma visfatin in diabetics. Methods The study subjects included T2DM patients with mild lower limb atherosclerosis (n=38, T2DM-MLAD), with severe LA (n = 32, T2DM SLAD), without LA (n= 42, T2DM) and healthy control (n = 40, NC). ABI, serum visfatin, IMT of lower limbs by ultrosound and general clinical data were determined. Results Serum visfatin showed a similar level [(46.79±7. 7)vs (50.86 ± 11.65) ng/ml, P〉 0. 051 between NC and T2DM groups, and a gradually lower levels from T2DM-SLAD to T2DM-MLAD to T2DM groups[(67.21±16.67)vs(58.75±13.52)vs(50.86± 11.65) ng/ml respectively, intergroup comparison: all〈0. 05]. Serum visfatin was positively correlated with IMT of lower limbs, IR,HbA1c,FIns and WHR. Conclusion Serum visfatin is a risk factor for lower limb atherosclerosis and positively correlated with severity of lower limb atherosclerosis. Ankle-brachial index is decreasing along with the progressing of lower limb atherosclerosis.
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2011年第2期112-115,117-119,共4页 Chinese Journal of Diabetes
关键词 糖尿病 2型 下肢血管病变 内脏脂肪素 内膜中层厚度 下肢动脉 Diabetes mellitus, type 2 Lower limb vascular disease Visfatin Intima-media thickness, Lower limbs
  • 相关文献

参考文献9

  • 12007年版中国2型糖尿病防治指南[J].中华内分泌代谢杂志,2008,24(2). 被引量:268
  • 2谭擎缨,王静,阮芸,余秀华.2型糖尿病下肢血管病变的超声检查及相关因素研究[J].中华糖尿病杂志(1006-6187),2005,13(6):416-417. 被引量:25
  • 3Fukuhara A,Matsuda M,Nishizawa M,et al.visfatin:a protein secreted by visceral fat that mimics the effects of insulin.Science,2005,307:426-430.
  • 4Haide DG,Schindler K,Sehaller G,et al.Increased Dlasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding.J Clin Endocrinol Metab,2006,91:1578-1581.
  • 5Filippatos TD,Derdemezis CS,Kiortsis DN,et al.Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome.J Endocrinol Invest,2007,30:323-326.
  • 6Oki K,Yamane K,Kamei N,et al,Circulating visfatin level is correlated with inflammation,but not with insulin resistance.Clin Endoerinol(Oxf),2007,67:796-800.
  • 7Alghasham AA,Barakat YA.Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.Saudi Med J,2008,29:185-192.
  • 8Dahl TB,Yndestad A,Skjelland M,et al.Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis:possible role in inflammation and plaque destabilization.Circulation,2007,115:972-980.
  • 9Zhong M,Tan HW.Gong HP,et al.Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis.Clin Endocrinol,2008,69:878-884.

二级参考文献5

共引文献291

同被引文献15

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部